Clinical Trials Logo

Clinical Trial Summary

LSCSI is a Hub&Spoke project with the main aim to improve the outcome of patients with cardiogenic shock in Lower Silesia region, Poland. It consists of one "hub" which is Wroclaw University Hospital and eleven "spokes" which are eleven cardiology departments situated in Lower Silesian Voivodeship. The consortium have unified protocol defining which cardiogenic shock patient and when should be transferred to the "hub" for enhanced treatment options including durable mechanical circulatory support or heart transplant. The "hub" have 7/24 Shock Team on-site supplied with a protocol how to proceed with "spoke" transferred patients including decision making on which mechanical circulatory support implant with subsequent de-escalation or escalation pathway.


Clinical Trial Description

LSCSI is a Hub&Spoke project with the main aim to improve the outcome of patients with cardiogenic shock in Lower Silesia region, Poland. It consists of one "hub" which is Wroclaw University Hospital and eleven "spokes" which are eleven cardiology departments situated in Lower Silesian Voivodeship. The consortium have unified protocol defining which cardiogenic shock patient and when should be transferred to the "hub" for enhanced treatment options including durable mechanical circulatory support or heart transplant. Shared cardiogenic shock definition: 1. Systolic blood pressure < 90 mmHg for > 30 minutes or need for vasopressors use to maintain systolic blood pressure > 90 mmHg 2. Lactate level > 2.0 mmol/L 3. Pulmonary capillary wedge pressure or left ventricle end diastolic pressure > 15 mmHg (excluding pulmonary embolism) 4. Cardiac Index ≤ 2.2 l/min/m2 5. Diuresis < 30 ml/h 6. Clinical signs of peripheral hypoperfusion Data required by "hub" from "spoke" 1. Echocardiography with data on left and right ventricle function 2. Current aortic and mixed venous blood gases 3. Pulmonary artery catheter measurements including calculation of cardiac power, pulmonary artery pulsatile index, cardiac output, cardiac index, pulmonary artery wedge pressure, pulmonary vascular resistance, systemic vascular resistance (excluding pulmonary embolism) 4. Peripheral blood tests including liver and kidney function, morphology, troponin, natriuretic peptides 5. Currently used and possible for use vascular accesses 6. For pulmonary embolism: computed tomography of pulmonary arteries Upon telephone contact "hub" shock team decides on patients transfer or further treatment in "spoke" facility. When decision on transfer is taken shock team members gather at emergency room when patient arrives and decides on treatment options according to shock team protocol. As a "hub" Wroclaw University Hospital provides mechanical circulatory support (Intra-aortic balloon pump, Impella CP (Cardiac Power), Impella 5.0, Impella RP (Right Pump), ECMO (ExtraCorporeal Membrane Oxygenation), Levitronix, HeartMate3) together with heart transplant program as a regional reference center for advanced heart failure patients. Additionally for acute pulmonary embolism complicated by shock "hub" provides peripheral or local thrombolysis and in case of contraindication for thrombolysis - transcatheter thrombectomy or surgical embolectomy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05465200
Study type Observational [Patient Registry]
Source Wroclaw Medical University
Contact Wiktor Kuliczkowski
Phone +48717331112
Email wiktor.kuliczkowski@umed.wroc.pl
Status Recruiting
Phase
Start date January 1, 2022
Completion date January 1, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT02301819 - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05728359 - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A